Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025
In 2009, monoclonal antibodies for cancer therapy generated total revenues of over $18bn worldwide. From 2010, that sector will benefit from new drugs and expanding indications for existing products. Cancer incidence and prevalence are rising worldwide; studies reveal that incidence will rise by up to 40% by 2025. Worldwide, the treatment of cancer is a priority for healthcare providers, with high demand for efficacious and well-tolerated therapies. Where is the monoclonal antibody therapy market for cancer heading - technologically and commercially - from 2010 onwards? Our new report covers such questions, providing the information that you need.
Our new report - Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential. There remain many unmet therapeutic needs in the treatment of cancer. There is also increasing demand for cancer monoclonal antibodies in developing countries. Novel monoclonal antibodies that demonstrate improved safety profiles – combined with high efficacies – can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2025, our new report explains.
Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 covers the following monoclonal antibodies in detail:
Comprehensive analysis of the market for monoclonal antibodies in cancer therapy
Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 examines this sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipelines and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 45 tables and figures included, as well as two interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025
This report gives you the following benefits in particular:
Our new report - Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential. There remain many unmet therapeutic needs in the treatment of cancer. There is also increasing demand for cancer monoclonal antibodies in developing countries. Novel monoclonal antibodies that demonstrate improved safety profiles – combined with high efficacies – can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2025, our new report explains.
Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 covers the following monoclonal antibodies in detail:
- Avastin
- Mabthera/Rituxan
- Herceptin
- Erbitux
- Vectibix
- Campath.
Comprehensive analysis of the market for monoclonal antibodies in cancer therapy
Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 examines this sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipelines and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 45 tables and figures included, as well as two interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025
This report gives you the following benefits in particular:
- You will assess the current market for monoclonal antibodies in cancer therapy
- You will review the overall market from 2010 to 2025, including global sales forecasts
- You will receive sales forecasts for the leading products in that market from 2010 to 2025, with discussions of market potential and competition
- You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions
- You will analyse the drivers, restraints, competition and opportunities influencing the market sector
- You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered
- You will discover the most-exciting R&D pipeline developments
- You will receive expert views on the sector, including full interview transcripts from our survey.
1. EXECUTIVE SUMMARY
1.1 Monoclonal Antibodies in Cancer Therapy: Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research & Analysis Methods
2. INTRODUCTION TO MONOCLONAL ANTIBODIES FOR CANCER THERAPY
2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales
2.2 The Oncology Market is Growing
2.3 Monoclonal Antibodies
2.3.1 What are Monoclonal Antibodies?
2.3.2 How do Monoclonal Antibody Therapies Work?
2.4 Categories of Monoclonal Antibodies for Therapeutic Use
2.4.1 Murine Antibodies
2.4.2 Chimeric and Humanised Antibodies
2.4.3 Fully Human Antibodies
2.4.4 Immunogenicity
2.5 Current Monoclonal Antibody Cancer Therapies
2.5.1 Avastin
2.5.2 MabThera/Rituxan
2.5.3 Herceptin
2.5.4 Erbitux
2.5.5 Vectibix
2.5.6 Campath
2.5.7 Mylotarg
2.5.8 Zevalin
2.5.9 Bexxar
2.5.10 Arzerra
2.5.11 TheraCIM
2.5.12 Removab
3. CANCER THERAPY MABS: WORLD MARKET PROSPECTS, 2010-2025
3.1 The Market for Monoclonal Antibodies in Cancer Therapy, 2009
3.2 The Biotech Market is Expanding Rapidly
3.2.1 Monoclonal Antibodies – Leading Class in the Pharma Biotech Market
3.2.2 Oncology is a Major Sales Driver in the Monoclonal Antibodies Market
3.3 Cancer Therapy MAbs: Market Forecast, 2010-2025
3.4 The Big Three Monoclonal Antibodies in Cancer Therapy
3.5 Generic Competition
3.6 Chimeric Antibodies
3.7 The Shift Towards Human Antibodies
4. THE LEADING MONOCLONAL ANTIBODIES IN CANCER THERAPY, 2010-2025
4.1 The Leading Four Monoclonal Antibodies Accounted for 34% of the Global Cancer Drug Market in 2009
4.2 Avastin (Bevacizumab)
4.2.1 Avastin Leads the Market for Monoclonal Antibodies in Cancer Therapy
4.2.2 Avastin Will Show High Growth – But Will it Last?
4.3 MabThera/Rituxan (Rituximab)
4.3.1 MabThera/Rituxan Sales Forecast, 2010-2015
4.3.2 Long-Term Prospects for MabThera/Rituxan, 2015-2025
4.3.3 Competition for MabThera/Rituxan
4.3.4 Biosimilar MabThera/Rituxan
4.4 Herceptin (Trastuzumab)
4.4.1 Short Term Forecast for Herceptin
4.4.2 Long Term Prospects for Herceptin, 2015-2025
4.4.3 Herceptin's Major Competitors, 2010-2025
4.5 Erbitux (Cetuximab)
4.5.1 Erbitux Sales Forecast, 2010-2015
4.5.2 Erbitux Sales Forecast, 2015-2025
4.5.3 Erbitux’ Major Competitors, 2010-2025
4.6 Vectibix (Panitumumab)
4.6.1 Vectibix Sales Forecast, 2010-2025
4.7 Campath (Alemtuzumab)
4.7.1 Campath Sales Forecast, 2010-2025
4.8 Chapter Summary – The Leading Monoclonal Antibodies in Cancer Therapy, 2010-2025
5. SWOT ANALYSIS
5.1 Key Market Drivers
5.1.1 The High Profile of Cancer
5.1.2 The Increasing Prevalence of Cancer
5.1.3 The High Economic Cost of Cancer
5.1.4 Drug Prices
5.1.5 Improvements in Accessibility
5.1.6 Incremental Improvements in Treatment in the Absence of a Complete Cure
5.1.7 New Production Methods Will Reduce Costs
5.1.8 Biologicals versus Chemically-Derived Pharmaceutical Products
5.1.9 Combining Existing Products
5.1.10 Monoclonal Antibodies Have a Lower Risk of Adverse Effects
5.1.11 Promising Pipelines
5.1.12 Personalised Medicine
5.2 Key Market Restraints
5.2.1 High Development Costs
5.2.2 Financial Limitations in Research and Development
5.2.3 Research Bias and 'Me-Too' Drugs
5.2.4 Risk Sharing
5.2.5 Public Health Initiatives
5.2.6 Competition is Fierce for Many Targets
5.2.7 Insufficient Efficacy as Monotherapies
5.2.8 Immunogenicity
5.2.9 Safety Concerns
5.2.10 Mode of Administration is a Limiting Factor
5.2.11 Biosimilar Monoclonal Antibodies
6. CANCER MABS IN THE LEADING NATIONAL PHARMACEUTICAL MARKETS, 2010-2025
6.1 Leading National Markets for Cancer Monoclonal Antibodies, 2009
6.2 National Market Forecasts, 2010-2025
6.3 US Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
6.4 Japanese Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
6.5 Cancer Monoclonal Antibody Markets in the Leading European Countries: Prospects, 2010-2025
6.6 Cancer Monoclonal Antibody Markets in China and India: Prospects, 2010-2025
7. R&D PIPELINE FOR MONOCLONAL ANTIBODY CANCER THERAPIES
7.1 New Technology – Monoclonal Antibody Fragments
7.1.1 Bispecific T-Cell Engagers
7.1.2 Tandabs
7.2 Conjugated versus Naked Antibodies
7.3 The Future of Fully Human MAbs
7.4 Competition for Prime Drug Targets
7.4.1 Tailored Medicine
7.5 Late-Stage Pipeline: Additional and Expanded Indications
7.5.1 Avastin
7.5.2 MabThera/Rituxan
7.5.3 Herceptin
7.5.4 Erbitux
7.6 Late-Stage R&D Pipeline Review
7.6.1 Dalotuzumab
7.6.2 Galiximab
7.6.3 Ipilimumab
7.6.4 Ramucirumab
7.6.5 Zalutumumab
8. EXPERT OPINIONS
8.1 Dr Mark Cragg
8.1.1 How Do Monoclonal Antibodies Treat Cancer?
8.1.2 The Future of Different Monoclonal Antibody Types
8.1.3 Threats and Limitations
8.1.4 Opportunities
8.1.5 Will Side Effects Limit Growth?
8.1.6 Future Developments
8.2 Dr Janice M. Reichert
8.2.1 Main Challenges
8.2.2 Main Opportunities
8.2.3 Side Effects
8.2.4 Future Developments and Pipelines
8.2.5 The Effect of Biosimilars
9. CONCLUSIONS
9.1 The Monoclonal Antibody Market, 2010-2025
9.2 Sales Growth for Monoclonal Antibody Cancer Therapies
9.3 The Monoclonal Antibody R&D Pipeline for Cancer Treatment
9.4 Expansion into Emerging Markets
9.5 Personalised Treatments
9.6 Future Prospects
1.1 Monoclonal Antibodies in Cancer Therapy: Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research & Analysis Methods
2. INTRODUCTION TO MONOCLONAL ANTIBODIES FOR CANCER THERAPY
2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales
2.2 The Oncology Market is Growing
2.3 Monoclonal Antibodies
2.3.1 What are Monoclonal Antibodies?
2.3.2 How do Monoclonal Antibody Therapies Work?
2.4 Categories of Monoclonal Antibodies for Therapeutic Use
2.4.1 Murine Antibodies
2.4.2 Chimeric and Humanised Antibodies
2.4.3 Fully Human Antibodies
2.4.4 Immunogenicity
2.5 Current Monoclonal Antibody Cancer Therapies
2.5.1 Avastin
2.5.2 MabThera/Rituxan
2.5.3 Herceptin
2.5.4 Erbitux
2.5.5 Vectibix
2.5.6 Campath
2.5.7 Mylotarg
2.5.8 Zevalin
2.5.9 Bexxar
2.5.10 Arzerra
2.5.11 TheraCIM
2.5.12 Removab
3. CANCER THERAPY MABS: WORLD MARKET PROSPECTS, 2010-2025
3.1 The Market for Monoclonal Antibodies in Cancer Therapy, 2009
3.2 The Biotech Market is Expanding Rapidly
3.2.1 Monoclonal Antibodies – Leading Class in the Pharma Biotech Market
3.2.2 Oncology is a Major Sales Driver in the Monoclonal Antibodies Market
3.3 Cancer Therapy MAbs: Market Forecast, 2010-2025
3.4 The Big Three Monoclonal Antibodies in Cancer Therapy
3.5 Generic Competition
3.6 Chimeric Antibodies
3.7 The Shift Towards Human Antibodies
4. THE LEADING MONOCLONAL ANTIBODIES IN CANCER THERAPY, 2010-2025
4.1 The Leading Four Monoclonal Antibodies Accounted for 34% of the Global Cancer Drug Market in 2009
4.2 Avastin (Bevacizumab)
4.2.1 Avastin Leads the Market for Monoclonal Antibodies in Cancer Therapy
4.2.2 Avastin Will Show High Growth – But Will it Last?
4.3 MabThera/Rituxan (Rituximab)
4.3.1 MabThera/Rituxan Sales Forecast, 2010-2015
4.3.2 Long-Term Prospects for MabThera/Rituxan, 2015-2025
4.3.3 Competition for MabThera/Rituxan
4.3.4 Biosimilar MabThera/Rituxan
4.4 Herceptin (Trastuzumab)
4.4.1 Short Term Forecast for Herceptin
4.4.2 Long Term Prospects for Herceptin, 2015-2025
4.4.3 Herceptin's Major Competitors, 2010-2025
4.5 Erbitux (Cetuximab)
4.5.1 Erbitux Sales Forecast, 2010-2015
4.5.2 Erbitux Sales Forecast, 2015-2025
4.5.3 Erbitux’ Major Competitors, 2010-2025
4.6 Vectibix (Panitumumab)
4.6.1 Vectibix Sales Forecast, 2010-2025
4.7 Campath (Alemtuzumab)
4.7.1 Campath Sales Forecast, 2010-2025
4.8 Chapter Summary – The Leading Monoclonal Antibodies in Cancer Therapy, 2010-2025
5. SWOT ANALYSIS
5.1 Key Market Drivers
5.1.1 The High Profile of Cancer
5.1.2 The Increasing Prevalence of Cancer
5.1.3 The High Economic Cost of Cancer
5.1.4 Drug Prices
5.1.5 Improvements in Accessibility
5.1.6 Incremental Improvements in Treatment in the Absence of a Complete Cure
5.1.7 New Production Methods Will Reduce Costs
5.1.8 Biologicals versus Chemically-Derived Pharmaceutical Products
5.1.9 Combining Existing Products
5.1.10 Monoclonal Antibodies Have a Lower Risk of Adverse Effects
5.1.11 Promising Pipelines
5.1.12 Personalised Medicine
5.2 Key Market Restraints
5.2.1 High Development Costs
5.2.2 Financial Limitations in Research and Development
5.2.3 Research Bias and 'Me-Too' Drugs
5.2.4 Risk Sharing
5.2.5 Public Health Initiatives
5.2.6 Competition is Fierce for Many Targets
5.2.7 Insufficient Efficacy as Monotherapies
5.2.8 Immunogenicity
5.2.9 Safety Concerns
5.2.10 Mode of Administration is a Limiting Factor
5.2.11 Biosimilar Monoclonal Antibodies
6. CANCER MABS IN THE LEADING NATIONAL PHARMACEUTICAL MARKETS, 2010-2025
6.1 Leading National Markets for Cancer Monoclonal Antibodies, 2009
6.2 National Market Forecasts, 2010-2025
6.3 US Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
6.4 Japanese Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
6.5 Cancer Monoclonal Antibody Markets in the Leading European Countries: Prospects, 2010-2025
6.6 Cancer Monoclonal Antibody Markets in China and India: Prospects, 2010-2025
7. R&D PIPELINE FOR MONOCLONAL ANTIBODY CANCER THERAPIES
7.1 New Technology – Monoclonal Antibody Fragments
7.1.1 Bispecific T-Cell Engagers
7.1.2 Tandabs
7.2 Conjugated versus Naked Antibodies
7.3 The Future of Fully Human MAbs
7.4 Competition for Prime Drug Targets
7.4.1 Tailored Medicine
7.5 Late-Stage Pipeline: Additional and Expanded Indications
7.5.1 Avastin
7.5.2 MabThera/Rituxan
7.5.3 Herceptin
7.5.4 Erbitux
7.6 Late-Stage R&D Pipeline Review
7.6.1 Dalotuzumab
7.6.2 Galiximab
7.6.3 Ipilimumab
7.6.4 Ramucirumab
7.6.5 Zalutumumab
8. EXPERT OPINIONS
8.1 Dr Mark Cragg
8.1.1 How Do Monoclonal Antibodies Treat Cancer?
8.1.2 The Future of Different Monoclonal Antibody Types
8.1.3 Threats and Limitations
8.1.4 Opportunities
8.1.5 Will Side Effects Limit Growth?
8.1.6 Future Developments
8.2 Dr Janice M. Reichert
8.2.1 Main Challenges
8.2.2 Main Opportunities
8.2.3 Side Effects
8.2.4 Future Developments and Pipelines
8.2.5 The Effect of Biosimilars
9. CONCLUSIONS
9.1 The Monoclonal Antibody Market, 2010-2025
9.2 Sales Growth for Monoclonal Antibody Cancer Therapies
9.3 The Monoclonal Antibody R&D Pipeline for Cancer Treatment
9.4 Expansion into Emerging Markets
9.5 Personalised Treatments
9.6 Future Prospects
LIST OF TABLES
Table 2.1 Monoclonal Antibody Technologies – Overview, 2010
Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies, 2010
Table 3.1 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2016
Table 3.2 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2017-2025
Table 3.3 Leading MAbs in Cancer Therapy: Sales & Market Shares, 2009, 2015, 2020 & 2025
Table 3.4 Cancer Monoclonal Antibodies: Sales & Market Shares by Class, 2009
Table 4.1 Avastin Sales Forecast, 2010-2016
Table 4.2 Avastin Sales Forecast, 2017-2025
Table 4.3 MabThera Sales Forecast, 2010-2016
Table 4.4 MabThera Sales Forecast, 2017-2025
Table 4.5 Herceptin Sales Forecast, 2010-2016
Table 4.6 Herceptin Sales Forecast, 2017-2025
Table 4.7 Erbitux Sales Forecast, 2010-2016
Table 4.8 Erbitux Sales Forecast, 2017-2025
Table 4.9 Vectibix Sales Forecast, 2010-2016
Table 4.10 Vectibix Sales Forecast, 2017-2025
Table 4.11 Campath Sales Forecast, 2010-2016
Table 4.12 Campath Sales Forecast, 2017-2025
Table 5.1 SWOT Chart for Cancer Monoclonal Antibodies, 2010-2025
Table 5.2 Side Effects of Monoclonal Antibody Therapy, 2010
Table 5.3 The Importance of Personalised Medicine in Oncology, 2010
Table 6.1 Leading National Markets for Cancer MAbs: Sales, 2009
Table 6.2 Leading National Markets for Cancer MAbs: Sales Forecasts, 2010-2016
Table 6.3 Leading National Markets for Cancer MAbs: Sales Forecasts, 2017-2025
Table 6.4 Leading National Markets for Cancer MAbs: Sales & Market Shares, 2009, 2015, 2020 & 2025
Table 7.1 Cancer MAb R&D Pipeline: Promising Agents in Phase III, 2010
Table 2.1 Monoclonal Antibody Technologies – Overview, 2010
Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies, 2010
Table 3.1 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2016
Table 3.2 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2017-2025
Table 3.3 Leading MAbs in Cancer Therapy: Sales & Market Shares, 2009, 2015, 2020 & 2025
Table 3.4 Cancer Monoclonal Antibodies: Sales & Market Shares by Class, 2009
Table 4.1 Avastin Sales Forecast, 2010-2016
Table 4.2 Avastin Sales Forecast, 2017-2025
Table 4.3 MabThera Sales Forecast, 2010-2016
Table 4.4 MabThera Sales Forecast, 2017-2025
Table 4.5 Herceptin Sales Forecast, 2010-2016
Table 4.6 Herceptin Sales Forecast, 2017-2025
Table 4.7 Erbitux Sales Forecast, 2010-2016
Table 4.8 Erbitux Sales Forecast, 2017-2025
Table 4.9 Vectibix Sales Forecast, 2010-2016
Table 4.10 Vectibix Sales Forecast, 2017-2025
Table 4.11 Campath Sales Forecast, 2010-2016
Table 4.12 Campath Sales Forecast, 2017-2025
Table 5.1 SWOT Chart for Cancer Monoclonal Antibodies, 2010-2025
Table 5.2 Side Effects of Monoclonal Antibody Therapy, 2010
Table 5.3 The Importance of Personalised Medicine in Oncology, 2010
Table 6.1 Leading National Markets for Cancer MAbs: Sales, 2009
Table 6.2 Leading National Markets for Cancer MAbs: Sales Forecasts, 2010-2016
Table 6.3 Leading National Markets for Cancer MAbs: Sales Forecasts, 2017-2025
Table 6.4 Leading National Markets for Cancer MAbs: Sales & Market Shares, 2009, 2015, 2020 & 2025
Table 7.1 Cancer MAb R&D Pipeline: Promising Agents in Phase III, 2010
LIST OF FIGURES
Figure 3.1 Market Shares of the Monoclonal Antibody Therapeutic Areas, 2009
Figure 3.2 Sales of the Top Three Monoclonal Antibody Cancer Therapies, 2005-2009
Figure 3.3 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2025
Figure 3.4 Leading MAbs in Cancer Therapy: Market Shares, 2009
Figure 3.5 Leading MAbs in Cancer Therapy: Market Shares, 2025
Figure 3.6 MAbs in Cancer Therapy: Market Shares by Class, 2009
Figure 4.1 Avastin Sales Forecast, 2010-2025
Figure 4.2 MabThera Sales Forecast, 2010-2025
Figure 4.3 Herceptin Sales Forecast, 2010-2025
Figure 4.4 Erbitux Sales Forecast, 2010-2025
Figure 4.5 Vectibix Sales Forecast, 2010-2025
Figure 4.6 Campath Sales Forecast, 2010-2025
Figure 4.7 Leading MAbs in Cancer Therapy: Sales, 2009, 2015 & 2025
Figure 4.8 Leading MAbs in Cancer Therapy: Sales Forecasts, 2010-2025
Figure 6.1 Leading National Market Shares, 2009
Figure 6.2 Leading National Market Shares, 2015
Figure 6.3 Leading National Market Shares, 2025
Figure 6.4 US: MAbs in Cancer Therapy Sales Forecast, 2010-2025
Figure 6.5 Japan: MAbs in Cancer Therapy Sales Forecast, 2010-2025
Figure 6.6 Leading European Countries: MAbs in Cancer Therapy Sales Forecasts, 2010-2025
Figure 6.7 China & India: MAbs in Cancer Therapy Sales Forecasts, 2010-2025
COMPANIES LISTED
Abbott
Abgenix
Affimed
American Cancer Society
Amgen
AstraZeneca
Bayer
Bayer Schering Pharma
Biocon
Biogen Idec
BioTech Pharma
Bristol-Myers Squibb
Cell Therapeutics
Center of Molecular Immunology [Havana, Cuba]
Chugai
Corixa (Acquired by GSK)
Daiichi-Sankyo
Dr. Reddy's Laboratories
Elan Pharmaceuticals
Eli Lilly
Esteve
European Medicines Agency (EMEA)
Food and Drug Administration (FDA) [US]
Fresenius
Genentech
Genmab
Genzyme
GlaxoSmithKline
IDEC Pharmaceuticals
ILEX Oncology
ImClone Systems
International Agency for Research on Cancer
Johnson & Johnson
Lance Armstrong Foundation
mAbs
Medarex
Menarini
Merck & Co.
Merck KGaA
Millennium Pharmaceuticals
Morphotek
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
Novartis
Oncoscience AG
OSI Pharmaceuticals
Pfizer
Pierre Fabre
Roche
Southampton General Hospital [UK]
Spectrum Pharmaceuticals
State Food and Drug Administration (China State FDA)
Takeda
TeGenero
TRION Pharma
Tufts University
UCB
US Food and Drug Administration
World Health Organisation (WHO)
Wyeth
YM Biosciences
Zenyaku Kogyo
Figure 3.1 Market Shares of the Monoclonal Antibody Therapeutic Areas, 2009
Figure 3.2 Sales of the Top Three Monoclonal Antibody Cancer Therapies, 2005-2009
Figure 3.3 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2025
Figure 3.4 Leading MAbs in Cancer Therapy: Market Shares, 2009
Figure 3.5 Leading MAbs in Cancer Therapy: Market Shares, 2025
Figure 3.6 MAbs in Cancer Therapy: Market Shares by Class, 2009
Figure 4.1 Avastin Sales Forecast, 2010-2025
Figure 4.2 MabThera Sales Forecast, 2010-2025
Figure 4.3 Herceptin Sales Forecast, 2010-2025
Figure 4.4 Erbitux Sales Forecast, 2010-2025
Figure 4.5 Vectibix Sales Forecast, 2010-2025
Figure 4.6 Campath Sales Forecast, 2010-2025
Figure 4.7 Leading MAbs in Cancer Therapy: Sales, 2009, 2015 & 2025
Figure 4.8 Leading MAbs in Cancer Therapy: Sales Forecasts, 2010-2025
Figure 6.1 Leading National Market Shares, 2009
Figure 6.2 Leading National Market Shares, 2015
Figure 6.3 Leading National Market Shares, 2025
Figure 6.4 US: MAbs in Cancer Therapy Sales Forecast, 2010-2025
Figure 6.5 Japan: MAbs in Cancer Therapy Sales Forecast, 2010-2025
Figure 6.6 Leading European Countries: MAbs in Cancer Therapy Sales Forecasts, 2010-2025
Figure 6.7 China & India: MAbs in Cancer Therapy Sales Forecasts, 2010-2025
COMPANIES LISTED
Abbott
Abgenix
Affimed
American Cancer Society
Amgen
AstraZeneca
Bayer
Bayer Schering Pharma
Biocon
Biogen Idec
BioTech Pharma
Bristol-Myers Squibb
Cell Therapeutics
Center of Molecular Immunology [Havana, Cuba]
Chugai
Corixa (Acquired by GSK)
Daiichi-Sankyo
Dr. Reddy's Laboratories
Elan Pharmaceuticals
Eli Lilly
Esteve
European Medicines Agency (EMEA)
Food and Drug Administration (FDA) [US]
Fresenius
Genentech
Genmab
Genzyme
GlaxoSmithKline
IDEC Pharmaceuticals
ILEX Oncology
ImClone Systems
International Agency for Research on Cancer
Johnson & Johnson
Lance Armstrong Foundation
mAbs
Medarex
Menarini
Merck & Co.
Merck KGaA
Millennium Pharmaceuticals
Morphotek
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
Novartis
Oncoscience AG
OSI Pharmaceuticals
Pfizer
Pierre Fabre
Roche
Southampton General Hospital [UK]
Spectrum Pharmaceuticals
State Food and Drug Administration (China State FDA)
Takeda
TeGenero
TRION Pharma
Tufts University
UCB
US Food and Drug Administration
World Health Organisation (WHO)
Wyeth
YM Biosciences
Zenyaku Kogyo
